The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro‐oesophageal reflux disease

Background: Mosapride is a novel prokinetic agent facilitating acetylcholine release from the enteric cholinergic neurones through a selective 5‐HT4 receptor agonistic action. It is also active through its main metabolite M1, which is a 5‐HT3 antagonist. The importance of motor dysfunction in the pathogenesis of gastro‐oesophageal reflux disease (GERD) makes it interesting to examine the effect of mosapride on oesophageal acid exposure. Methods: The effect of mosapride on oesophageal 24‐h acid reflux variables was studied in 21 patients with GERD symptoms and a pre‐entry total acid exposure time (pH